Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
API-CAT: low-dose versus full-dose apixaban for extended treatment of cancer-associated thrombosis
2017-003342-25Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in cancer-associated thrombosis (CAT) and venous thromboembolism (VTE) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary efficacy endpoint. Started Apr 2018; status: completed.
02
Drugs
apixaban
03
Conditions
cancer-associated thrombosis (CAT)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2017-003342-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003342-25.